Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
2,897.00    45.00 (1.58%)
Bid:
2,892.00
Ask:
2,894.00
Spread: 2.00 (0.069%)
Market Cap: £4.04b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Form 8 (OPD) PLANT IMPACT PLC

26 Feb 2018 09:08

RNS Number : 8970F
Croda International PLC
26 February 2018
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

CRODA EUROPE LIMITED (OFFEROR, SUBSIDIARY OF

CRODA INTERNATIONAL PLC)

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

-

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PLANT IMPACT PLC (OFFEREE)

(d) Is the discloser the offeror or the offeree?

OFFEROR

(e) Date position held:

The latest practicable date prior to the disclosure

23/02/2018

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

-

-

-

-

(2) Cash-settled derivatives:

 

-

-

-

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

-

-

-

-

 

TOTAL:

-

-

-

-

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

-

Details, including nature of the rights concerned and relevant percentages:

-

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

None

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

26 February 2018

Contact name:

Conleth Campbell

Telephone number:

01405 860551

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEPGUMUPUPRUBQ
Date   Source Headline
11th Jun 20262:58 pmRNSDirector/PDMR Shareholding
11th Jun 20269:15 amRNSDirector Declaration
1st Jun 20261:46 pmRNSDirector/PDMR Shareholding
29th May 20264:06 pmRNSDirector/PDMR Shareholding
29th May 20263:10 pmRNSDirector/PDMR Shareholding
29th May 20261:53 pmRNSDirector/PDMR Shareholding
29th May 20261:52 pmRNSDirector/PDMR Shareholding
29th May 20261:45 pmRNSDirector/PDMR Shareholding
15th May 20269:23 amRNSDirector/PDMR Shareholding
12th May 202612:10 pmRNSDirector/PDMR Shareholding
6th May 20261:21 pmRNSDirector/PDMR Shareholding
23rd Apr 202611:20 amRNSResult of AGM
22nd Apr 20267:00 amRNSFirst quarter 2026 sales in line with expectations
13th Apr 20261:41 pmRNSDirector/PDMR Shareholding
31st Mar 202611:48 amRNSHolding(s) in Company
26th Mar 20264:34 pmRNSDirector/PDMR Shareholding
18th Mar 20263:31 pmRNSDirector/PDMR Shareholding
18th Mar 20263:30 pmRNSDirector/PDMR Shareholding
18th Mar 20263:27 pmRNSDirector/PDMR Shareholding
18th Mar 20263:25 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:20 pmRNSDirector/PDMR Shareholding
16th Mar 20261:36 pmRNSAnnual Financial Report
16th Mar 20261:36 pmRNSAnnual Financial Report
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
6th Mar 20261:32 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:13 pmRNSHolding(s) in Company
24th Feb 20267:00 amRNSResults for the year ended 31 December 2025
11th Feb 20262:59 pmRNSDirector/PDMR Shareholding
13th Jan 20262:47 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSDirector Declaration
11th Dec 202511:30 amRNSDirector/PDMR Shareholding
11th Nov 202511:19 amRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSThird quarter 2025 sales update
14th Oct 20251:58 pmRNSDirector/PDMR Shareholding
8th Oct 20254:26 pmRNSDirector/PDMR Shareholding
1st Oct 20253:45 pmRNSDirector/PDMR Shareholding
18th Sep 20253:49 pmRNSHolding(s) in Company
12th Sep 202510:11 amRNSDirector/PDMR Shareholding
11th Sep 20253:54 pmRNSDirector/PDMR Shareholding
29th Aug 20253:58 pmRNSHolding(s) in Company
29th Aug 202511:03 amRNSHolding(s) in Company
27th Aug 20251:58 pmRNSHolding(s) in Company
22nd Aug 20254:24 pmRNSDirector/PDMR Shareholding
22nd Aug 202511:55 amRNSDirector/PDMR Shareholding
14th Aug 20259:10 amRNSDirector/PDMR Shareholding
12th Aug 202511:42 amRNSDirector/PDMR Shareholding
7th Aug 20259:16 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.